Update on clinical, pathophysiological and therapeutic aspects in ANCA-associated vasculitides

Medicine and Dentistry

• Vasculitis 100%
• Neutrophil 100%
• Granulomatosis with Polyangiitis 60%
• ANCA Associated Vasculitis 60%
• Side Effect 40%
• Microscopic Polyangiitis 40%
• Immunosuppressive Treatment 40%
• Antibody 20%
• T Cell 20%
• Granulomatosis 20%
• Lymphatic Tissue 20%
• Tumor Necrosis Factor 20%
• Spontaneous Remission 20%
• Recurrence Risk 20%
• Biological Product 20%
• Cytokine 20%
• Chronic Inflammation 20%
• Staphylococcus aureus 20%
• Interleukin 17 20%
• CD20 20%

Immunology and Microbiology

• Neutrophil 100%
• Autoantibody 100%
• Vasculitis 100%
• Granulomatosis with Polyangiitis 42%
• Churg-Strauss Syndrome 28%
• Immunosuppressive Therapy 28%
• Lymphoid Tissue 14%
• Tumor Necrosis Factor 14%
• Interleukin 17 14%
• CD20 14%
• Interleukin 15 14%
• T Cell 14%
• Cytokine 14%
• Antibody 14%
• Rituximab 14%
• Biological Product 14%